| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We report that stem cell factor (SCF) suppresses upregulated MHC class II expression in IL-33-treated mast cells. BMMCs in the IL-3-containing medium were treated with IL-33 in the presence or absence of SCF for a further 10 days. Simultaneous treatment of the BMMCs with IL-33 and SCF suppressed MHC class II expression and antigen (Ag)-mediated degranulation induced by the IL-33 treatment. However, the expression of c-kit and ST2 and the Ag-IgE-mediated production of IL-6 were not affected. The mRNA expression and H4 acetylation state of the MHC class II transactivator (CIITA) promoters III and IV in the BMMCs were suppressed by the simultaneous treatment with IL-33 and SCF, and restored by further treatment with imatinib, a c-kit inhibitor. These results confirm that MHC class II expression in mast cells induced by IL-33 is reversible and that SCF is a very important stabilization or maturation factor for MCs.
|
